Evidence mapPaperPMID 39459433Full record

SynthesisMedicina (Kaunas, Lithuania)2024

Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis.

Guoguang Xiao, Shan Gao, Yongmei Xie, Zhiling Wang, Min Shu

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guoguang XiaoDepartment of Pediatrics, West China Second Hospital, Sichuan University, Chengdu 610041, China.
Shan GaoDepartment of Pediatrics, West China Second Hospital, Sichuan University, Chengdu 610041, China.
Yongmei XieDepartment of Pediatrics, West China Second Hospital, Sichuan University, Chengdu 610041, China.
Zhiling WangDepartment of Pediatrics, West China Second Hospital, Sichuan University, Chengdu 610041, China.
Min ShuDepartment of Pediatrics, West China Second Hospital, Sichuan University, Chengdu 610041, China.

Funding

Natural Science Foundation General Project of Sichuan Provincial Science and Technology De-partment 2024NSFSC0633Sichuan Medical Youth Innovation Project Q23055The Fundamental Research Funds for the Central Universities SCU2022F4080
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedHyperlipoproteinemia Type IIPCSK9 InhibitorsAdolescentAnticholesteremic AgentsChildCholesterol, LDLHumansProprotein Convertase 9Treatment OutcomealirocumabAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCholesterol, LDLevolocumabPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9alirocumabchildefficacyevolocumabfamilial hypercholesterolemiasafety

Identifiers

PMID39459433
PMCPMC11509226

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.